![](/fileadmin/_processed_/csm_HIV__63e20764dc.jpg)
Naobios and Sumagen partner to develop HIV vaccine
Under the contract, Naobios SAS will provide bioprocess development and GMP production of clinical batches of a virus-based HIV vaccine candidate...
![](/fileadmin/_processed_/csm_BMS_Evotec_072382e6ec.png)
Evotec SE cashes in €20m milestone
The partnership initiated in 2016 uses Evotec’s iPSC platform to create predictive patient-derived cell-based disease models that mimic the pathology...
![](/fileadmin/_processed_/csm_Neurosense-pipeline_38841e73e1.png)
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
![](/fileadmin/_processed_/csm_Adrenomed_cf30735df8.png)
Shock: Adrenomed AG gets FDA fast track designation
After Adrenomed AG has demonstrated that its septic shock treatment led to a 60% reduction in relative 28-day mortality vs. placebo in a stratified...
![](/fileadmin/_processed_/csm_Microglia_and_neurons_c__Gary_Shaw_ed89bb0973.jpg)
Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...
![](/fileadmin/_processed_/csm_Product_Award_winners_88844c23d2.png)
SLAS Europe 2024 honours products with most impact
Two companies were selected by the SLAS Europe 2024 jury from 13 applicants and six finalists as winners of this year's Product Award in Barcelona:...
![](/fileadmin/_processed_/csm_Nordic_Bioproducts_Group_f4678ba458.png)
Nordic Bioproducts Group opens its first production facility
Nordic Bioproduct’s commercial-scale manufacturing site is expected to create €40m in revenue in the first full operating year. In...